Current Drug Target -Inflammation & Allergy

Kurt S Zaenker
Institute of Immunology and Experimental Oncology
University Witten/Herdecke
Stockumerstraße 10
Witten, 58448


Glycosaminoglycans and the Regulation of Allergic Inflammation

Author(s): Mark J. Rose and Clive Page

Affiliation: Sackler Institute of PulmonaryPharmacology, GKT School of Biomedical Sciences, 5th Floor Hodgkin Building,Guy's Campus, London, SE1 9RT, UK


Glycosaminoglycans (GAGs) are large, polyanionic molecules expressed throughout the body. The GAG heparin, co-released with histamine, is synthesised by and stored exclusively in mast cells, whereas the closely related molecule heparan sulphate is expressed, as part of a proteoglycan, on cell surfaces and throughout tissue matrices. These molecules are increasingly thought to play a role in regulation of the inflammatory response and heparin like molecules are now being seriously considered to hold potential in the treatment of inflammatory diseases such as asthma. Heparin and related molecules have been found to exert anti-inflammatory effects in a wide range of in vitro assays, animal models and in human disease. The anti-inflammatory activities of heparin are independent of the well-established anticoagulant activity of heparin, suggesting that the separation of these properties could yield novel anti-inflammatory drugs, which may be useful in the future treatment of inflammatory diseases.

Keywords: glycosaminoglycans, allergic inflammation, polyanionic molecules, heparan sulphate, inflammatory diseases

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [221 - 225]
Pages: 5
DOI: 10.2174/1568010043343589
Price: $58